

# Azeez Farooki

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9340018/publications.pdf>

Version: 2024-02-01

36  
papers

1,698  
citations

394421

19  
h-index

361022

35  
g-index

36  
all docs

36  
docs citations

36  
times ranked

2350  
citing authors

#	ARTICLE	IF	CITATIONS
1	Real-world use of bone modifying agents in metastatic, castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 126-132.	3.9	6
2	Bone Mineral Density: Clinical Relevance and Quantitative Assessment. <i>Journal of Nuclear Medicine</i> , 2021, 62, 446-454.	5.0	25
3	Vertebral Fractures After Denosumab Discontinuation in Breast Cancer Survivors: A Single Institution Experience. <i>HSS Journal</i> , 2021, 17, 185-191.	1.7	1
4	Calcitriol Elevation Is Associated with a Higher Risk of Refractory Hypercalcemia of Malignancy in Solid Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e1115-e1123.	3.6	20
5	A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma. <i>Cancer</i> , 2020, 126, 4532-4544.	4.1	14
6	AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS—2020 UPDATE EXECUTIVE SUMMARY. <i>Endocrine Practice</i> , 2020, , .	2.1	1
7	Pituitary as a Source of HCG: Residual Levels After Bilateral Testicular Tumor Removal. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2019, 7, 232470961984141.	0.6	1
8	Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 135-141.	0.4	37
9	Antiresorptive agents' bone-protective and adjuvant effects in postmenopausal women with early breast cancer. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1125-1135.	2.4	9
10	Impact of Hematopoietic Stem Cell Transplant (HSCT) Vitamin D Algorithm on Vitamin D Levels of HSCT Patients—Part II. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S113-S114.	2.0	0
11	The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky021.	2.9	92
12	Assessing fracture risk in early stage breast cancer patients treated with aromatase-inhibitors: An enhanced screening approach incorporating trabecular bone score. <i>Journal of Bone Oncology</i> , 2017, 7, 32-37.	2.4	21
13	Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus. <i>Postgraduate Medicine</i> , 2017, 129, 159-168.	2.0	31
14	Retrospective Review of Atypical Femoral Fracture in Metastatic Bone Disease Patients Receiving Denosumab Therapy. <i>Oncologist</i> , 2017, 22, 438-444.	3.7	39
15	Maintaining Bone Health During Hormonal Therapy for Prostate Cancer. <i>Annals of Internal Medicine</i> , 2017, 167, 357.	3.9	2
16	Ga-68 DOTATOC PET/CT-Guided Biopsy and Cryoablation with Autoradiography of Biopsy Specimen for Treatment of Tumor-Induced Osteomalacia. <i>CardioVascular and Interventional Radiology</i> , 2016, 39, 1352-1357.	2.0	19
17	Osteonecrosis of the jaw in patients treated with denosumab for metastatic tumors to the bone: A series of thirteen patients. <i>Journal of Cranio-Maxillo-Facial Surgery</i> , 2016, 44, 265-270.	1.7	22
18	Severe Hypocalcemia Associated With Denosumab in Metastatic Castration-Resistant Prostate Cancer: Risk Factors and Precautions for Treating Physicians. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e305-e309.	1.9	30

#	ARTICLE	IF	CITATIONS
19	Denosumab and fracture risk in women with breast cancer. <i>Lancet</i> , The, 2015, 386, 2056-2057.	13.7	4
20	Natural history of small radioiodine-avid bone metastases that have no structural correlate on imaging studies. <i>Endocrine</i> , 2014, 47, 266-272.	2.3	24
21	Effects of tyrosine kinase inhibition on bone metabolism: untargeted consequences of targeted therapies. <i>Endocrine-Related Cancer</i> , 2014, 21, R247-R259.	3.1	66
22	NCCN Bone Health Task Force: Key Recommendations. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 813-816.	4.9	10
23	Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors. <i>Leukemia Research</i> , 2013, 37, 790-794.	0.8	24
24	NCCN Task Force Report: Bone Health in Cancer Care. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, S-1-S-50.	4.9	245
25	Risk assessment for severe hypocalcemia requiring hospitalization with denosumab. <i>Journal of Clinical Oncology</i> , 2013, 31, 115-115.	1.6	1
26	Skeletal-Related Events due to Bone Metastases from Differentiated Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 2433-2439.	3.6	113
27	Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway. <i>Journal of Clinical Oncology</i> , 2012, 30, 2919-2928.	1.6	188
28	Serum N-Telopeptide and Bone-Specific Alkaline Phosphatase Levels in Patients With Osteonecrosis of the Jaw Receiving Bisphosphonates for Bone Metastases. <i>Journal of Oral and Maxillofacial Surgery</i> , 2012, 70, 2768-2775.	1.2	15
29	Biochemical markers of bone turnover in osteonecrosis of the jaw in patients with osteoporosis and advanced cancer involving the bone. <i>Annals of the New York Academy of Sciences</i> , 2011, 1218, 80-87.	3.8	23
30	Atypical Subtrochanteric Femoral Fractures in Patients with Skeletal Malignant Involvement Treated with Intravenous Bisphosphonates. <i>Journal of Bone and Joint Surgery - Series A</i> , 2011, 93, 1235-1242.	3.0	92
31	NCCN Task Force Report: Bone Health in Cancer Care. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, S-1-S-32.	4.9	163
32	Osteonecrosis of the Maxilla and Mandible in Patients with Advanced Cancer Treated with Bisphosphonate Therapy. <i>Oncologist</i> , 2008, 13, 911-920.	3.7	135
33	Osteonecrosis of the Jaw Related to Bevacizumab. <i>Journal of Clinical Oncology</i> , 2008, 26, 4037-4038.	1.6	201
34	Anabolic Therapies for Osteoporosis. <i>New England Journal of Medicine</i> , 2007, 357, 2410-2411.	27.0	11
35	Insulin Resistance and Cancer-Related Mortality. <i>Journal of Clinical Oncology</i> , 2007, 25, 1628-1629.	1.6	5
36	Increased Cancer-Related Mortality for Patients With Type 2 Diabetes Who Use Sulfonylureas or Insulin: Response to Bowker et al.. <i>Diabetes Care</i> , 2006, 29, 1989-1990.	8.6	8